论文部分内容阅读
Objective To evaluate the potential benefit of prolonging 12-month dual antiplatelet therapy among patients with coronary artery disease receiving zotarolimus-eluting stents.Methods From Sep.2006 to Jue.2009, patients with coronary artery disease undergoing PCI with zotarolimus-eluting stents in the cardiology department of Beijing Anzhen Hospital were enrolled.Our clinical endpoint focused on major adverse cardiac or cerebrovascular events (MACCE), a composite of death, nonfatal myocardial infarction (MI), stroke, and repeat revascularization.Follow up was carried out by telephone or outpatient interview.To overcome the defect of non-randomized comparisons, multivariable Cox proportional-hazards regression was carried out to adjust for potential confounding factors.Results The average follow-up was 28.4±7.4 months.A toal of 915 appropriate patients were divided to two groups: 12-month DAPT group (362) and >12-month DAPT group (553).Rates of MACCE (6.1% VS.5.0%, p=0.87), Death/MI/Stroke (2.3% VS.2.0% p=0.99), and TVR (3.9% VS.2.8%, p=0.97) did not differ between 12-month DAPT group and >12-month DAPT group.After adjusted by the multivariable Cox proportional-hazards regression, still no significant differences of the endpoints mentioned above were observed between the two groups.Conclusion: The use of dual antiplatelet therapy for a period longer than 12 months in patientswho had received Zotarolimus-eluting stents was not significantly more effective than aspirinmonotherapy in reducing adverse cardiac or cerebrovascular event.